Incruse Ellipta Dosage
Generic name: UMECLIDINIUM BROMIDE 62.5ug
Dosage form: aerosol, powder
Drug class: Anticholinergic bronchodilators
Medically reviewed by Drugs.com. Last updated on Dec 13, 2023.
The recommended dosage of INCRUSE ELLIPTA for maintenance treatment of COPD is 1 actuation (umeclidinium 62.5 mcg) once daily by oral inhalation.
- •
- INCRUSE ELLIPTA should be used at the same time every day. Do not use INCRUSE ELLIPTA more than 1 time every 24 hours.
- •
- No dosage adjustment is required for geriatric patients, patients with renal impairment, or patients with moderate hepatic impairment.
More about Incruse Ellipta (umeclidinium)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (34)
- Side effects
- During pregnancy
- FDA approval history
- Drug class: anticholinergic bronchodilators
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
See also:
Symbicort
Symbicort (budesonide and formoterol) is used to prevent bronchospasm in people with asthma or ...
Ventolin
Ventolin is used for asthma, acute, asthma, maintenance, bronchiectasis, bronchospasm prophylaxis ...
Breztri Aerosphere
Breztri (budesonide/glycopyrrolate/formoterol fumarate) is a combination inhaler used for the ...
Ventolin HFA
Ventolin HFA (albuterol) is used to treat or prevent breathing problems in patients who have asthma ...
Dupixent
Dupixent is used to treat eczema, eosinophilic or oral-corticosteroid-dependent asthma, chronic ...
Breo Ellipta
Breo Ellipta (fluticasone and vilanterol) is used to prevent airflow obstruction or bronchospasm in ...
Spiriva
Spiriva (tiotropium) is used to prevent bronchospasm in people with bronchitis, emphysema, or COPD ...
Anoro Ellipta
Anoro (umeclidinium and vilanterol inhalation powder) is used to treat chronic obstructive ...
Xopenex
Xopenex is a short-acting bronchodilator used to treat or prevent bronchospasm in asthma and other ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
